HGG-08. COMBINATORIAL ACTIVITY OF CDK4/6-INHIBITORS AND TRAMETINIB IN PEDIATRIC HIGH-GRADE GLIOMA WITH BRAFV600E MUTATION AND HOMOZYGOUS CDKN2A DELETION

BRAFV600E mutations occur in 10-15% and homozygous CDKN2A deletions in approximately 40% of adolescent and pediatric high-grad glioma (HGG) and is associated with significantly decreased overall survival. Moreover, a subset of pHGG is defined by combined BRAFV600E mutation and concomitant CDKN2A hom...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayr, Lisa, Mager, Leah, Gabler, Lisa, Madlener, Sibylle, Berger, Julia, Kirchhofer, Dominik, Lämmerer, Anna, Bruckner, Katharina, Lötsch, Daniela, Berger, Walter, Gojo, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: High Grade Glioma/Gliomatosis Cerebri - HGG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260149/
http://dx.doi.org/10.1093/neuonc/noad073.157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260149/
http://dx.doi.org/10.1093/neuonc/noad073.157

Ejemplares similares